Invesco
DERM icon

Invesco’s Journey Medical DERM Stock Holding History

Invesco’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86.7K Buy
18,496
+1,970
+12% +$15.3K ﹤0.01% 3639
2025
Q4 		$127K Buy
+16,526
New +$130K ﹤0.01% 3610

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invesco's DERM Position: Q1 2026 in Review

Invesco increased its Journey Medical (DERM) stake by 12% in Q1 2026, buying an estimated $15.3K and bringing the position to 18,496 shares worth $86.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3639.

Invesco first reported a position in DERM in Q4 2025 and has held it in 2 quarters since. The position peaked at $127K in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q1 2026.

  • Invesco held 18,496 shares of Journey Medical worth $86.7K as of Q1 2026.
  • Invesco bought 1,970 Journey Medical shares in Q1 2026, an estimated $15.3K.
  • Journey Medical made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3639 holding.
  • Invesco first reported a position in Journey Medical in Q4 2025 and has held it in 2 quarters since.
  • Invesco's Journey Medical position peaked at $127K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.